Epidemiology in the pharmaceutical industry: a perspective for infectious diseases.
As access to observational data and databases expands so does the need for epidemiologists in industry. As an example, in the U.K. arm of the Department of Epidemiology at GlaxoWellcome Research and Development, the number of PhD-trained epidemiologists increased from zero in 1996 to eight in 1999. Their remit is often broad, including designing and co-ordinating, pharmacoepidemiologic research, studies of risk factors for disease and disease progression and pregnancy registries. Where appropriate, existing data sources, such as research databases, are employed for studies. Otherwise, primary data collection is pursued using standard methodology, for example, cross-sectional, case-control and cohort studies. This paper describes a structure for epidemiologic research in the pharmaceutical industry, the role of the industry epidemiologist and the scope of epidemiological studies. Two examples of observational studies of HSV-2/HIV interactions are given, and implications for research agendas discussed. The pharmaceutical industry is becoming increasingly committed to epidemiological research, and research agendas often involve extensive collaboration with leading external academic and public health groups.
Robinson
N J
NJ
Worldwide Epidemiology, GlaxoWellcome Research and Development, Greenford Road, Greenford, Middlesex UB6 OHE, UK. jnr86737@glaxowellcome.co.uk
D000293:Adolescent; D000328:Adult; D017954:Africa South of the Sahara / Q000453:epidemiology; D003141:Communicable Diseases / Q000453:epidemiology*; D019992:Databases as Topic; D004345:Drug Industry / Q000379:methods*; D004813:Epidemiology; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology; D006558:Herpes Genitalis / Q000150:complications / Q000453:epidemiology; D018258:Herpesvirus 2, Human / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors